Abstracts Archive - Page 708 of 2607 - ACR Meeting Abstracts

Abstract Number: 1946 • ACR Convergence 2021
Therapeutic Drug Monitoring Compared to Standard Infliximab Therapy in Patients with Immune-mediated Inflammatory Diseases: A Randomized Controlled Trial
Silje Watterdal Syversen¹, Guro Goll¹, Kristin Jørgensen², Marthe Brun¹, Øystein Sandanger³, Kristin Hammersbøen², Joseph Sexton¹, Inge Olsen³, Johanna Gehin⁴, David Warren³, Rolf Anton Klaasen³, Trude Bruun⁵, Maud Kristine Ljoså⁶, Anne Haugen⁷, Rune Njålla⁸, Brigitte Michelsen⁹, Camilla Zettel¹⁰, Yngvill Bragenes¹¹, Svanaug Skorpe¹², Eldri Strand¹³, Pawel Mielnik¹⁴, Cato Mørk¹⁵, Tore Kvien¹, Jørgen Jahnsen², Nils Bolstad¹⁶ and Espen Haavardsholm¹, ¹Diakonhjemmet Hospital, Oslo, Norway, ²Akershus University Hospital, Lørenskog, Norway, ³Oslo University Hospital, Oslo, Norway, ⁴Oslo University Hospital, Lillehammer, Nepal, ⁵The University Hospital of North Norway, Tromsø, Norway, ⁶Dept. of Rheumatology, Ålesund Hospital, Ålesund, Norway, ⁷Østfold Hospital Trust, Moss, Norway, ⁸Nordland Hospital Trust, Bodø, Bodø, Norway, ⁹Hospital of Southern Norway Trust, Kristiansand, Norway, ¹⁰Betanien Hospital, Skien, Norway, ¹¹Vestre Viken Hospital Trust, Drammen, Norway, ¹²Haugesund Hospital for Rheumatic Diseases, Haugesund, Norway, ¹³Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway, ¹⁴Førde Hospital Trust, Førde, Norway, ¹⁵Akershus Dermatology Center, Lørenskog, Norway, ¹⁶Oslo University Hospital, Radiumhospitalet, Oslo, Norway
Background/Purpose: Proactive therapeutic drug monitoring (TDM), a treatment strategy based on scheduled assessments of serum drug levels, has been proposed to optimize efficacy and safety…
Abstract Number: 1944 • ACR Convergence 2021
Sustained Remission/Low Disease Activity Is Feasible in the Long Term in Patients with Psoriatic Arthritis Treated with IL-23/12 Inhibition with Ustekinumab (STELARA®) and Tumor Necrosis Factor Inhibitors in a Real-World, Multicenter Study
Josef Smolen¹, Paul Bergmans², Kurt de Vlam³, Elisa Gremese⁴, Beatriz Joven-Ibáñez⁵, Tatiana Korotaeva⁶, Wim Noël⁷, Michael Nurmohamed⁸, Petros Sfikakis⁹, Stefan Siebert¹⁰, Elke Theander¹¹ and Laure Gossec¹², ¹Medical University of Vienna, Vienna, Austria, ²Janssen-Cilag BV, Breda, Netherlands, ³University Hospitals Leuven, Leuven, Belgium, ⁴Fondazione Policlinico A Gemelli-IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy, ⁵University Hospital 12 de Octubre, Madrid, Spain, ⁶VA Nasonova Research Institute of Rheumatology, Moscow, Russia, ⁷Janssen Pharmaceutica, HEMAR Department, Beerse, Belgium, ⁸Reade and Amsterdam University Medical Center, location VUmc, Amsterdam, Netherlands, ⁹National Kapodistrian University of Athens Medical School, Athens, Greece, Athens, Greece, ¹⁰University of Glasgow, Glasgow, United Kingdom, ¹¹Janssen Cilag, Lund, Sweden, ¹²Sorbonne Université and Hôpital Pitié-Salpêtrière, Paris, France
Background/Purpose: Among treatment options for PsA, IL-23/12 inhibition with ustekinumab (UST) was the first new biologic after TNF inhibitors (TNFi). Few data compare long-term effectiveness…
Abstract Number: 1941 • ACR Convergence 2021
The Risk of Venous Thromboembolic Events in Patients with RA Aged ≥ 50 Years with ≥ 1 Cardiovascular Risk Factor: Results from a Phase 3b/4 Randomized Safety Study of Tofacitinib vs TNF Inhibitors
Christina Charles-Schoeman¹, Roy Fleischmann², Eduardo Mysler³, Maria Greenwald⁴, Cunshan Wang⁵, All-shine Chen⁵, Carol A Connell⁵, John C Woolcott⁶, Sujatha Menon⁵, Yan Chen⁷, Kristen Lee⁷ and Zoltan Szekanecz⁸, ¹Department of Medicine, University of California, Los Angeles, Los Angeles, CA, ²Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, ³Organización Médica de Investigación, Buenos Aires, Argentina, ⁴Desert Medical Advances, Palm Desert, CA, ⁵Pfizer Inc, Groton, CT, ⁶Pfizer Inc, Collegeville, PA, ⁷Pfizer Inc, New York, NY, ⁸Division of Rheumatology, University of Debrecen, Faculty of Medicine, Debrecen, Hungary
Background/Purpose: ORAL Surveillance (NCT02092467) was a randomized, open-label, non-inferiority, Phase 3b/4 study that assessed the relative risk of major adverse cardiovascular (CV) events (MACE) and…
Abstract Number: 1934 • ACR Convergence 2021
Intra-Individual Change in Cognitive Function Among Adults with Systemic Lupus Erythematosus: A Markov Analysis over 7 Years
Stefan Perera¹, Richard Cook², Ker-Ai Lee², Patricia Katz³ and Zahi Touma⁴, ¹Division of General Internal Medicine, University of Toronto, Toronto, ON, Canada, ²Department of Statistics and Actuarial Sciences, University of Waterloo, Waterloo, ON, Canada, ³University of California San Francisco, San Francisco, CA, ⁴University of Toronto, Mississauga, ON, Canada
Background/Purpose: Cognitive impairment is a prevalent neuropsychiatric manifestation of SLE. Studies have primarily focused on the prevalence of cognitive impairment cross-sectionally; however, there remain gaps…
Abstract Number: PP05 • ACR Convergence 2021
Fighting Health-Related Misinformation Using Social Media / How Creating an Online Group for Patients with Relapsing Polychondritis — and Moderating It with Health Professionals — Helps Spread Reliable and Empowering Information
Michael Linn¹, Spenser Mestel² and Susie Ratledge³, ¹Relapsing Polychondritis Foundation, New York, NY, ²New York, NY, ³Relapsing Polychondritis: Secular Science and Support group, Chattanooga, TN
Background/Purpose: Before I became ill in 2017, I was a registered nurse with a degree in health science who'd often educate patients about how they…
Abstract Number: PP02 • ACR Convergence 2021
Leveraging Digital Health Tracking to Improve Arthritis Management
Katie Roberts, Annapolis, MD
Background/Purpose: I was diagnosed with psoriasis when I was age 10 in 1986. At that time, my treatment plan consisted of regular application of Eucerin…
Abstract Number: PP07 • ACR Convergence 2021
How Online Spanish-Language Resources Got Me and My RA Through the COVID-19 Pandemic
Wigna Cruz, Puerto Rico
Background/Purpose: I was experiencing joint pain especially in my wrists, which led me to see my physician for testing. Initially I was misdiagnosed with lupus.…
Abstract Number: PP09 • ACR Convergence 2021
Family Planning while Living with Rheumatoid Arthritis
Shannan O'Hara-Levi, Monroe, NY
Background/Purpose: Over the course of my 30+ years living with Polyarticular Juvenile Rheumatoid Arthritis, I have never had long term success on any one biologic treatment,…
Abstract Number: PP08 • ACR Convergence 2021
Should I Get the COVID-19 Vaccine With My RA? Using Evidence-Based Resources for Decision-Making
Aberdeen Allen, Colgate Palmolive, Parlin, NJ
Background/Purpose: Patients with autoimmune rheumatic diseases have concerns about getting the COVID-19 vaccine. As vaccines began to receive emergency use authorization, individuals with conditions like…
Abstract Number: PP06 • ACR Convergence 2021
Collaborative Advocacy Helps Me and Other Patients With Relapsing Polychondritis (“RP”’) / My life improved by helping the RP Foundation and Race for RP facilitate awareness, education, and research to improve the quality of life for patients with RP and advance a cure for this disease.
Michael Linn¹ and Dan Smith², ¹Relapsing Polychondritis Foundation, New York, NY, ²Relapsing Polychondritis Foundation, Canton, MI
Background/Purpose: In March 2020, I was diagnosed as having relapsing polychondritis ("RP"), an understudied, underdiagnosed, and undertreated debilitating autoimmune disease that can be fatal if…
Abstract Number: PP04 • ACR Convergence 2021
Dual Roles: Thriving with SLE as a Medical Student
Chieh Lo¹ and Song-Chou Hsieh², ¹School of Medicine, I-Shou Univerity, Kaohsiung, Taiwan (Republic of China), ²Division of Immunology, Allergy and Rheumatology, Department of Medicine, National Taiwan University Hospital, Taipei, Taiwan (Republic of China)
Background/Purpose: A few days after my 18th birthday, I walked into a rheumatology clinic for the first time. I had ulcers in my mouth, felt…
Abstract Number: PP10 • ACR Convergence 2021
Discovering ‘I’ Through Interaction with Support Group Members: A Place of Empathy That Transcends the Limitations of Words
Noriko Okochi¹, Eiji Oishi² and Mika Ishiguro¹, ¹Rheumatic Disease and Vasculitis Support Network Japan, Tokyo, Japan, ²Rheumatic Disease and Vasculitis Support Network Japan, Yamaguchi, Japan
Background/Purpose: Since 5-year-old, I have had unexplained symptoms. At the age of 13, my whole body became inflamed. The pain was so intense that I…
Abstract Number: PP11 • ACR Convergence 2021
“Our Arthritis May Be Chronic but We Are Definitely Iconic” – Two Teens Created a National Podcast for Youth with Rheumatic Diseases
Trishtha Peters¹ and Natasha Trehan², ¹University of Ontario, Toronto, ON, Canada, ²University of Ottawa, Toronto, ON, Canada
Background/Purpose: Trish Peters was diagnosed with JIA at 11. She has been on Methotrexate to lessen disease activity for her knees and hands. She does…
Abstract Number: PP03 • ACR Convergence 2021
Navigating Maintenance of a Rare Autoimmune Rheumatic Disease in the Context of the COVID-19 Pandemic
Ida Hakkarinen, Greenbelt, MD
Background/Purpose: On March 13th, 2020, the President of the United States issued a proclamation declaring that the outbreak of coronavirus disease 2019 (COVID-19) was a…
Abstract Number: 1933 • ACR Convergence 2021
Association Between Race/Ethnicity and COVID-19 Outcomes in Systemic Lupus Erythematosus (SLE) in United States Patients: Data from the COVID-19 Global Rheumatology Alliance
Manuel Ugarte-Gil¹, Graciela Alarcn², Andrea Seet³, Zara Izadi³, Ali Duarte-Garcia⁴, Emily Gilbert⁵, Maria Valenzuela-Almada⁶, Leanna Wise⁷, Jeffrey Sparks⁸, Tiffany Hsu⁹, Kristin D'Silva¹⁰, Naomi Patel¹⁰, Emily Sirotich¹¹, Jean Liew¹², Jonathan Hausmann¹³, Paul Sufka¹⁴, Rebecca Grainger¹⁵, Suleman Bhana¹⁶, Wendy Costello¹⁷, Zachary Wallace¹⁸, Lindsay Jacobsohn¹⁹, Anja Strangfeld²⁰, Elsa Frazão Mateus²¹, Kimme Hyrich²², Laure Gossec²³, Loreto Carmona²⁴, Saskia Lawson-Tovey²², Lianne Kearsley-Fleet²⁵, Martin Schaefer²⁶, Pedro Machado²⁷, Philip Robinson²⁸, Milena Gianfrancesco³ and Jinoos Yazdany³, ¹Hospital Guillermo Almenara Irigoyen, Essalud/Universidad Científica del Sur, Lima, Peru, ²University of Alabama at Birmingham, Birmingham, AL, ³University of California San Francisco, San Francisco, CA, ⁴Mayo Clinic, Rochester, MN, ⁵Mayo Clinic, Jacksonville, FL, ⁶Division of Rheumatology, Mayo Clinic, Rochester, MN, ⁷LAC+USC/Keck Medicine of USC, Pasadena, CA, ⁸Brigham and Women's Hospital, Boston, MA, ⁹Brigham and Women's Hospital, Jamaica Plain, MA, ¹⁰Massachusetts General Hospital, Boston, MA, ¹¹McMaster University, Hamilton, ON, Canada, ¹²Boston University, Boston, MA, ¹³Boston Children's Hospital / Beth Israel Deaconess Medical Center, Cambridge, MA, ¹⁴HealthPartners, Eagan, MN, ¹⁵University of Otago, Wellington, New Zealand, ¹⁶Crystal Run Health, Montvale, NJ, ¹⁷Irish Children's Arthritis Network, Bansha, Ireland, ¹⁸Massachusetts General Hospital, Newton, MA, ¹⁹University of California San Francisco, Antioch, CA, ²⁰Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, ²¹Liga Portuguesa Contra as Doenças Reumáticas (LPCDR), Lisbon, Portugal, ²²University of Manchester, Manchester, United Kingdom, ²³Sorbonne Université; APHP, Rheumatology Department, Pitié-Salpêtrière Hospital, Paris, France, ²⁴Instituto de Salud Musculoesqueltica (InMusc), Madrid, Spain, ²⁵Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom, ²⁶German Rheumatism Research Center, Berlin, Germany, ²⁷Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, United Kingdom, ²⁸Faculty of Medicine, The University of Queensland, Herston, Australia
Background/Purpose: Hispanic and African American race/ethnicities have been associated with poor COVID-19 outcomes in the general population and in rheumatic disease patients within the COVID-19…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].